Factor v leiden as a common genetic risk factor for venous thromboembolism

Journal of Nursing Scholarship

Volumn 38, Issue 1, 2006, Pages 19-25

  Horne III, McDonald K ^a   McCloskey, Donna Jo ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF NURSING RESEARCH   (United States)

Author keywords

APC resistance; FVL; Thrombophilia

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CAUCASIAN; ESTROGEN THERAPY; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HEALTH; HETEROZYGOTE DETECTION; HUMAN; INCIDENCE; MIDDLE AGED; NURSE ATTITUDE; PATIENT EDUCATION; PATIENT SELECTION; PEDIGREE; PREVALENCE; RISK FACTOR; STATISTICS; THROMBOEMBOLISM; VEIN THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGE DISTRIBUTION; AGED; ANTICOAGULANTS; ESTROGEN REPLACEMENT THERAPY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FACTOR V; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HETEROZYGOTE DETECTION; HUMANS; INCIDENCE; MIDDLE AGED; NURSE'S ROLE; PATIENT EDUCATION; PATIENT SELECTION; PEDIGREE; PREVALENCE; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS; WORLD HEALTH;

EID: 33645160030     PISSN: 15276546     EISSN: 15475069     Source Type: Journal    
DOI: 10.1111/j.1547-5069.2006.00072.x     Document Type: Article

References (51)

1. Ament, L. (2003). Factor V Leiden: A review of the literature. Journal of Prenatal and Neonatal Nursing, 17(3), 190-195.
2. Andersen, B.S., Steffensen, F.H., Sorensen, H.T., Nielsen, G.L., & Olsen, J. (1998). The cumulative incidence of venous thromboembolism during pregnancy and pueperium. Acta Obstetricia et Gynecologica Scandinavica, 77, 170-173.
3. Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. (2003). No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation, 107, 1117-1122.
4. Bertina, R.M., Koeleman, B.P.C., Koster, T., Rosendal, F.R., Dirven, R.J., de Ronde, H., et al. (1994). Mutation in blood coagulation Factor V associated with resistance to activated protein C. Nature, 369, 64-67.
5. Brill-Edwards, P., Ginsberg, J.S., Gent, M., Hirsh, J., Burrows, R., Kearon, C., et al. (2000). Safety of withholding heparin in pregnant women with a history of venous thromboembolism. New England Journal of Medicine, 343, 1439-1444.
6. Comp, P.C., Nixon, R.R., Cooper, M.R., & Esmon, C.T. (1984). Familial protein S deficiency is associated with recurrent thrombosis. Journal of Clinical Investigation, 74, 2082-2088.
7. Dahlback, B., Carlsson, M., & Svensson, P.J. (1993). Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a co-factor to activated protein C. Proceedings of the National Academy of Science, 90, 1004-1008.
8. Dahlback, B., & Hildebrand, B. (1994). Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of Factor V. Proceedings of the National Academy of Science, 91, 1396-1400.
9. de Visser, M.C.H., Rosendaal, F.R., & Bertina, R.M. (1999). A reduced sensitivity for activated protein C in the absence of Factor V Leiden increases the risk of venous thrombosis. Blood, 93, 1271-1276.
10. Egeberg, O. (1965). Inherited antithrombin deficiency causing thrombophilia. Thrombosis Diathesis Haemorrhagica, 13, 516-530.
11. Eekhoff, E.M.W., Rosendaal, F.R., & Vanderbroucke, J.P. (2000). Minor events and the risk of deep venous thrombosis. Thrombosis and Haemostasis, 83, 408-411.
12. Eichinger, S., Pabinger, I., Stumpflen, A., Hirschl, M., Bialonczyk, C., Schneider, B., et al. (1997). The risk of recurrent venous thromboembolism in patients with and without Factor V Leiden. Thrombosis and Haemostasis, 77, 624-628.
13. Emmerich, J., Rosendaal, F.R., Cattaneo, M., Margaglione, M., De Stefano, V., Cumming, T., et al. (2001). Combined effect of Factor V Leiden and Prothrombin 20210A on the risk of venous thromboembolism. Thrombosis and Haemostasis, 86, 809-816.
14. Green, D. (2001). Genetic hypercoagulability: Screening should be an informed choice. Blood, 98, 20.
15. Greengard, J.S., Eichinger, S., Griffin J.H., & Bauer, K.A. (1994). Brief report: Variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg ->Gln mutation in the gene for Factor V. New England Journal of Medicine, 331, 1559-1562.
16. Griffin, J.H., Evatt, B., Zimmerman, T.S., Kleiss, A.J., & Wideman, C. (1981). Deficiency of protein C in congenital thrombotic disease. Journal of Clinical Investigation, 68, 1370-1373.
17. Gris, J-C., Mercier, E., Quere, I., Lavigne-Lissalde, G., Cochery-Nouvellon, E., Hoffet, M., et al. (2004). Low-molecular-weight heparin versus lowdose aspirin in women with one fetal loss and constitutional thrombophilic disorder. Blood, 103, 3695-3699.
18. Grody, W.W., Griffin, J.H., Taylor. A.K., Ko, B.R., & Heit, J.A. (2001). American College of Medical Genetics consensus statement on Factor V Leiden mutation testing. Genetic Medicine, 3(2), 139-148.
19. Heit, J.A., Melton J, Lohse, C.M., Petterson T.M., Silverstein M.D., Mohr, D.N., et al. (2001). Incidence of venous thromboembolism in hospitalized patients vs. community residents. Mayo Clinic Proceedings, 76, 1102-1110.
20. Hyers, T.M., Agnelli, G., Hull, R.D., Morris, T.A., Samama, M., Tapson, V., et al. (2001). Antithrombotic therapy for venous thromboembolic disease. Chest, 119, 176S-193S.
21. Kerlin, B.A., Yan, S.B., Isermann, B.H., Brandt, J.T., Sood, R., Basson, B.R., et al. (2003). Survival advantage associated with heterozygous Factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood, 102, 3085-3092.
22. Kujovich, J.L. (2004). Factor V Leiden thrombophilia. Retrieved January 12, 2005, from www.genetests.org
23. Kupfermine, M.J., Eldor, A., Steinman, N., Many, A., Bar-Am, A., Jaffa, A., et al. (1999). Increased frequency of genetic thrombophilia in women with complications of pregnancy. New England Journal of Medicine, 340, 9-13.
24. Lindqvist, P., Dahlback, B., & Marsal, K. (1999). Thrombotic risk during pregnancy: A population study. Obstetrics and Gynecology, 94, 595-599.
25. Lindqvist, P., Zoller, B., & Dahlback, B. (2001). Improved hemoglobin status and reduced menstrual blood loss among female carriers of Factor V Leiden - an evolutionary advantage? Thrombosis and Haemostasis, 86, 1122-1123.
26. McColl, M.D., Ramsay, J.E., Tait, R.C., Walker, I.D., McCall, F., Conkie, J.A., et al. (1997). Risk factors for pregnancy associated with venous thromboembolism. Thrombosis and Haemostasis, 78, 1183-1188.
27. Macklon, N.S., & Greer, I.A. (1996). Venous thromboembolic disease in obstetrics and gynaecology: The Scottish experience. Scottish Medical Journal, 41, 83-86.
28. Martinelli, I., De Stefano, V., Taioli, E., Faciaroni, K., Rossi, E., & Mannucci, P.M. (2002). Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thrombosis and Haemostasis, 87, 791-795.
29. Martinelli, I., Legnani, C., Bucciarelli, P., Grandone, E., de Stefano, V., & Mannucci, P.M. (2001). Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thrombosis and Haemostasis, 86, 800-803.
30. Martinelli, I., Taioli, E., Cetin, I., Marinoni, A., Gerosa, S., Villa, M.V., et al. (2000). Mutations in coagulation factors in women with unexplained late fetal loss. New England Journal of Medicine, 343, 1015-1018.
31. Nichols, W.C., Amano, K., Cacheris, P.M., Pigueiredo, M.S., Michaelides, K., Schwaab, R., et al. (1996). Moderation of hemophilia A phenotype by the Factor V R506Q mutation. Blood, 88, 1183-1187.
32. Olsen, J.D. (2002). College of American pathologists consensus conference XXXVI: Diagnostic issues in thrombophilia. Archives of Pathology and Laboratory Medicine, 126, 1277-1280.
33. Pawar, A.R., Shetty, S., Ghosh, K., & Mohanty, D. (2001). How old is Factor V Leiden mutation? Thrombosis and Haemostasis, 86, 1591-1592.
34. Prandoni, P., Lensing, A.W.A., Cogo, A., Cuppinin, S., Villalta, S., Carta, M., et al. (1996). The long-term clinical course of acute deep venous thrombosis. Annals of Internal Medicine, 125, 1-7.
35. Rees, D.C. (1996). The population genetics of Factor V Leiden. British Journal of Haemotology, 95, 579-586.
36. Rees, D.C., Liu, Y.T., Cox, M.J., Elliott, P., & Wainscoat, J.S. (1997). Factor V Leiden and thermolabile methyltetrahydrofolate reductase in extreme old age. Thrombosis and Haemostasis, 78, 1357-1359.
37. Rey, E., Kahn, S.R., David, M., & Shrier, I. (2003). Thrombophilic disorders and fetal loss: A meta-analysis. Lancet, 361, 901-908.
38. Ridker, P.M., Glynn, R.J., Miletich, J.P., Goldhaber, S.Z., Stampfer, M.J., & Hennekens, C.H. (1997). Age-specific incidence rates of venous thromboembolism among heterozygous carriers of Factor V Leiden mutation. Annals of Internal Medicine, 126, 528-531.
39. Ridker, P.M., Goldhaber, S.Z., Danielson, E., Rosenberg, Y., Eby, C.S., Deitcher, S.R., et al. (2003). Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. New England Journal of Medicine, 348, 1425-1434.
40. Rodeghiero, P., & Tosetto, A. (1999). Activated protein C resistance and Factor V Leiden mutation are independent risk factors for venous thromboembolism. Annals of Internal Medicine, 130, 643-650.
41. Roest, M., Banga, J.D., Tempelman, M.J., de Groot, P.G., Grobbee, D.E., Sixma, J.J., et al. (1999). Factor V Arg506Gln mutation is not associated with cardiovascular mortality in older women. American Journal of Epidemiology, 149, 665-670.
42. Rosendaal, F.R., Koster, T., Vandenbroucke, J.P., & Reitsma, P.H. (1995). High risk of thrombosis in patients homozygous for Factor V Leiden (activated protein C resistance). Blood, 85, 1504-1508.
43. Rosendaal, F.R., Vessey, M., Rumley, A., Daly, E., Woodward, M., Heimerhorst, F.M., et al. (2002). Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. British Journal of Haemotology, 116, 851-854.
44. Svensson, P.J., Zoller, B., & Dahlback, B. (1997). Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thrombosis and Haemostasis, 77, 332-325.
45. Tirado, I., Mateo, J., Soria, J.M., Oliver, A., Borrell, M., Coll, I., et al. (2001). Contribution of prothrombin 20210A allele and Factor V Leiden mutation to thrombosis risk in thrombophilic families with other hemostatic deficiencies. Haematologica, 86, 1200-1208.
46. Vandenbroucke, J.P., Koster, T., Briet, E., Reitsma, P.H., Bertina, R.M., & Rosendaal, P.R. (1994). Increased risk of venous thrombosis in oralcontraceptive users who are carriers of Factor V Leiden mutation. Lancet, 344, 1453-1457.
47. Vanderbroucke, J.P., van der Meer, F.J.M., Helmerhorst, P.M., & Rosendaal, F.R. (1996). Factor V Leiden: Should we screen oral contraceptive users and pregnant women? British Medical Journal, 313, 1127-1130.
48. Williams, E.M., Steenblock, K.J., Brown, T., & Billings, P.R. (2004). Inherited venous thrombosis. Retrieved July 14, 2004, from www.advanceweb.com
49. Wilmer, M., Stocker, C., Buhler, B., Conell, B., & Calatzis, A. (2004). Improved distinction of Factor V wild type and Factor V Leiden using a novel prothrombin-based activated protein C resistance assay. American Journal of Clinical Pathology, 122, 836-842.
50. Zivelin, A., Griffin, J.H., Xu, X., Pabinger, I., Samama, M., Conard, J., et al. (1997). A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood, 89, 397-402.
51. Zoller, B., Svensson, P.J., He, X., & Dahlback, B. (1994). Identification of the same Factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. Journal of Clinical Investigation, 94, 2521-2524.